Survey of Darvadstrocel for treating Crohn's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study surveys the use of Darvadstrocel injections in patients with Crohn's disease who have complicated anal fistulas. Conducted in Japan, the study aims to monitor side effects and assess symptom improvement over a period of 36 months. Participants will receive Darvadstrocel according to their clinic's standard practices, while the study sponsor will provide guidelines for data collection. The focus is on real-world outcomes rather than controlled treatment conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria All patients with complex perianal fistulas in Crohn's Disease who received Darvadstrocel will be included.

Exclusion Criteria None

Where it's running

• Takeda selected site
  Tokyo, Tokyo, Japan Recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Iron treatment for children and young adults with Crohn’s disease and iron deficiency anemia

  This study tests how different iron treatment approaches work for kids and young adults with Crohn’s disease and iron deficiency anemia.

  Recruiting Phase 4 Weill Medical College of Cornell University · New York, New York · NCT07925450

• Autologous intestinal organoids applied to Crohn's ulcers in a first-in-human dose-escalation study

  This early-phase study tests a patient-derived intestinal organoid therapy (ATORM-C) delivered during colonoscopy to Crohn’s ulcers to see if it is safe and tolerable and to get a sense of healing.

  Recruiting Phase 1 Organoidsciences LTD. · Seoul · NCT07822087

• SL-325 in Crohn's Disease: a phase 2 test for adults with moderate to severe disease

  This phase 2 study tests SL-325 against placebo in adults with moderately to severely active Crohn's disease to see if it helps improve symptoms and disease activity.

  Recruiting Phase 2 Shattuck Labs, Inc. · Little Rock, Arkansas and 19 other locations · NCT07753850

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

• Stop PPI in active IBD: can you safely go without acid-suppressing meds?

  This study tests whether people with inflammatory bowel disease who have been on proton pump inhibitors can stop taking them and still manage their symptoms.

  Recruiting Phase 4 University of Nottingham · Nottingham · NCT07691138

• Tabellvi for moderate to severe Crohn's disease in Chinese adults

  This real-world, single-arm study tests Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease to see how often side effects occur and whether many patients reach remission by week 26.

  Recruiting Phase 4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Fuyang, Anhui and 6 other locations · NCT07663526

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.